Literature DB >> 15540688

Chronic lower extremity ischemia: a human model of ischemic tolerance.

Amit Badhwar1, Thomas L Forbes, Marge B Lovell, Alison A Dungey, Sarah D McCarter, Jeffrey R Scott, Guy DeRose, Kenneth A Harris, Richard F Potter.   

Abstract

BACKGROUND: Ischemic preconditioning (IPC) has been found in animals to have a protective effect against future ischemic injury to muscle tissue. Such injury is unavoidable during some surgical procedures. To determine whether chronic ischemia in the lower extremities would imitate IPC and reduce ischemic injury during vascular surgery, we designed a controlled clinical study. PATIENTS AND METHODS: Two groups of patients at a university-affiliated medical centre with chronic lower-extremity ischemia served as models of IPC: 6 patients awaiting femoral distal bypass (FDB) and 4 scheduled for aortobifemoral (ABF) bypass grafting for aortoiliac occlusive disease. Seven patients undergoing elective open repair of an infrarenal abdominal aortic aneurysm (AAA) were chosen as non-IPC controls. Three hematologic indicators of skeletal-muscle injury, lactate dehydrogenase (LDH), creatine kinase (CK) and myoglobin, were measured before placement of the proximal clamp, during surgical ischemia, immediately upon reperfusion, 15 minutes after and 1 hour after reperfusion, and during the first, second and third postoperative days.
RESULTS: Baseline markers of skeletal-muscle injury were similar in all groups. In postreperfusion samples, concentrations of muscle-injury markers were significantly lower in the 2 PC groups than in the control group. For example, at day 2, LDH levels were increased by about 30% over baseline measures in the elective AAA (control) group, whereas levels in the FDB and ABF groups remained statistically unchanged from baseline. Myoglobin in controls had increased by 977%, but only by 160% in the FDB and 528% in the ABF groups. CK levels, in a similar trend, were 1432% higher in the control group and only 111% (FDB) and 1029% (ABF) in the study groups. Taken together, these data represent a significant level of protection.
CONCLUSIONS: Patients with chronic lower-extremity ischemia suffered less severe ischemic injury after a period of acute ischemia than those with acute ischemia alone. Ischemic preconditioning is one proposed mechanism to help explain this protective effect.

Entities:  

Mesh:

Year:  2004        PMID: 15540688      PMCID: PMC3211936     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  58 in total

1.  Protective effect of liver ischemic preconditioning on liver and lung injury induced by hepatic ischemia-reperfusion in the rat.

Authors:  C Peralta; N Prats; C Xaus; E Gelpí; J Roselló-Catafau
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

2.  NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium.

Authors:  R Motterlini; R Foresti; M Intaglietta; R M Winslow
Journal:  Am J Physiol       Date:  1996-01

3.  Ischemic preconditioning and the beta-adrenergic signal transduction pathway.

Authors:  A Lochner; S Genade; E Tromp; T Podzuweit; J A Moolman
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

4.  Renal ischemia/reperfusion up-regulates heme oxygenase-1 (HSP32) expression and increases cGMP in rat heart.

Authors:  V S Raju; M D Maines
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

5.  Development of ischemia/reperfusion tolerance in the rat small intestine. An epithelium-independent event.

Authors:  D L Osborne; T Y Aw; G Cepinskas; P R Kvietys
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.

Authors:  G F Baxter; M S Marber; V C Patel; D M Yellon
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

7.  Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.

Authors:  M S Marber; D S Latchman; J M Walker; D M Yellon
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

8.  Pretreatment of human myocardium with adenosine during open heart surgery.

Authors:  H T Lee; R J LaFaro; G E Reed
Journal:  J Card Surg       Date:  1995-11       Impact factor: 1.620

9.  Intestinal preconditioning is mediated by a transient increase in nitric oxide.

Authors:  G Hotter; D Closa; M Prados; L Fernández-Cruz; N Prats; E Gelpí; J Roselló-Catafau
Journal:  Biochem Biophys Res Commun       Date:  1996-05-06       Impact factor: 3.575

10.  Operative mortality rates after elective infrarenal aortic reconstructions.

Authors:  T S Huber; T R Harward; T C Flynn; J L Albright; J M Seeger
Journal:  J Vasc Surg       Date:  1995-09       Impact factor: 4.268

View more
  3 in total

1.  Preconditioning the human brain: practical considerations for proving cerebral protection.

Authors:  Sebastian Koch
Journal:  Transl Stroke Res       Date:  2010-09       Impact factor: 6.829

2.  Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial.

Authors:  Selma Tülü; Miriam Mulino; Daniel Pinggera; Markus Luger; Philipp Würtinger; Astrid Grams; Thomas Bodner; Ronny Beer; Raimund Helbok; Raffaella Matteucci-Gothe; Claudia Unterhofer; Elke Gizewski; Erich Schmutzhard; Claudius Thomé; Martin Ortler
Journal:  Trials       Date:  2015-12-29       Impact factor: 2.279

3.  Allogeneic transplantation of programmable cells of monocytic origin (PCMO) improves angiogenesis and tissue recovery in critical limb ischemia (CLI): a translational approach.

Authors:  Rouven Berndt; Lars Hummitzsch; Katharina Heß; Martin Albrecht; Karina Zitta; Rene Rusch; Beke Sarras; Andreas Bayer; Jochen Cremer; Fred Faendrich; Justus Groß
Journal:  Stem Cell Res Ther       Date:  2018-04-27       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.